secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2026-07-30T20:06:54+00:00
Accession:  0001628280-26-051045
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M
--------------------------------------------------------------------------------

- Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.
- Core test reports (DecisionDx-Melanoma, TissueCypher) up 32% YoY; TissueCypher reports surged 63% to 14,988.
- Raises FY2026 revenue guidance to $365-375M from $345-355M; expects positive Adjusted EBITDA in Q3, Q4, and full year.
- Adjusted EBITDA $12.4M vs $10.4M; cash $266.8M.
- AdvanceAD-Tx test received NYSDOH approval; first patient enrolled in DETECT-AD study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/0001628280-26-051045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/cstl-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer